By Fineline Cube 
Youjia Biomedical Technology and Hangzhou Tongee Medical Technology Co., Ltd officially signed a strategic cooperation agreement to collaborate on applying Youjia Bio’s innovative small nucleic acid drug R&D platform to metabolic diseases, with an initial focus on diabetes.
Partnership Overview
| Element | Details |
|---|---|
| Companies | Youjia Bio + Hangzhou Tongee Medical Technology Co., Ltd |
| Technology | Small nucleic acid drug R&D platform |
| Therapeutic Focus | Metabolic diseases (diabetes) |
| Collaboration Scope | Drug design, preclinical studies, clinical trials, commercialization |
| Strategic Goal | Accelerate innovative drug development from discovery to market |
Technology Platform & Drug Profile
Youjia Bio’s Nucleic Acid Platform:
- Enables targeted modulation of disease pathways at the genetic level
- Designed for high specificity and reduced off-target effects
- Potential for once-daily or less frequent dosing in chronic diseases
Application in Metabolic Diseases:
- Targets key pathways in diabetes pathogenesis beyond current GLP-1 and insulin therapies
- Addresses unmet need for disease-modifying treatments
- Oral or injectable nucleic acid formulations in development
Strategic Rationale & Synergies
| Company | Strengths | Contribution |
|---|---|---|
| Youjia Bio | Leading nucleic acid drug development technology | Platform expertise, drug design, preclinical development |
| Tongee Medical | Extensive clinical resources, deep market understanding in metabolic diseases | Clinical validation, trial execution, market access, commercialization |
Synergy Benefits:
- Efficient Transition: Streamlined path from early discovery to clinical validation
- Resource Optimization: Leverages complementary capabilities to reduce development costs and timelines
- Market Alignment: Tongee’s clinical insights ensure drug development meets real-world patient needs
Development Roadmap
| Phase | Activities | Timeline |
|---|---|---|
| Drug Design | Target identification, nucleic acid sequence optimization | Q1-Q2 2026 |
| Preclinical | Pharmacology, toxicology, formulation development | H2 2026 |
| Clinical Trials | Phase I/II studies in diabetes patients | 2027-2028 |
| Commercialization | Regulatory filing, market launch preparation | 2029+ |
Market Context & Competitive Landscape
- Diabetes Market: China has >140 million diabetic patients; market valued at ¥50 billion (≈ US$7 billion)
- Nucleic Acid Drugs: Emerging class with potential for disease modification; currently dominated by GLP-1 analogs and insulin
- Competitive Advantage: First nucleic acid platform specifically tailored for metabolic diseases in China
- Unmet Need: Limited disease-modifying options; nucleic acid approach could offer long-acting, targeted therapy
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the collaboration’s development timelines, technology advancement, and commercial prospects. Actual results may differ due to research outcomes, regulatory processes, and competitive dynamics.-Fineline Info & Tech